EUVIMEDEUVIMED entdecken
Crossref

The heritage of glatiramer acetate and its use in multiple sclerosis

Giancarlo Comi, Maria Pia Amato, Antonio Bertolotto, Diego Centonze, Nicola De Stefano, Cinthia Farina, Paolo Gallo, Angelo Ghezzi, Luigi Maria Grimaldi, Gianluigi Mancardi, Maria Giovanna Marrosu, Enrico Montanari und 6 weitere

Multiple Sclerosis and Demyelinating Disorders · 2016

DOI: 10.1186/s40893-016-0010-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Multiple Sclerosis and Demyelinating Disorders, 2016. Verfasst von Giancarlo Comi und 17 weiteren Autor:innen. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 116 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Multiple sclerosis (MS) is a chronic and progressively debilitating disease of the central nervous system. Treatment of MS involves disease-modifying therapies (DMTs) to reduce the incidence of relapses and prevent disease progression. Glatiramer acetate (Copaxone®) was the first of the currently approved DMTs to be tested in human subjects, and it is still considered a standard choice for first-line treatment. The mechanism of action of glatiramer acetate appears to be relatively complex and has not been completely elucidated, but it is likely that it involves both immunomodulating and neuroprotective properties. The efficacy of glatiramer acetate 20 mg/mL once daily as first-line treatment in relapsing-remitting MS is well established, with ample evidence of efficacy from both placebo-controlled and active-comparator controlled clinical trials as well as real-world studies. There is also a considerable body of evidence indicating that the efficacy of glatiramer acetate is maintained in the long term. Clinical trial and real-world data have also consistently shown glatiramer acetate to be safe and well tolerated. Notably, glatiramer acetate has a good safety profile in women planning a pregnancy, and is not associated with foetal toxicity. Until recently, glatiramer acetate was only approved as 20 mg/mL once daily, but a new formulation with less frequent administration, 40 mg/mL three times weekly, has been developed and is now approved in many countries, including Italy. This review examines the mechanism of action, clinical efficacy, safety and tolerability of glatiramer acetate to provide suggestions for optimizing the use of this drug in the current MS therapeutic scenario.

Zitieren

APA

Comi, G., Amato, M. P., Bertolotto, A., Centonze, D., Stefano, N. D., Farina, C., Gallo, P., Ghezzi, A., Grimaldi, L. M., Mancardi, G., Marrosu, M. G., Montanari, E., Patti, F., Pozzilli, C., Provinciali, L., Salvetti, M., Tedeschi, G., & Trojano, M. (2016). The heritage of glatiramer acetate and its use in multiple sclerosis. Multiple Sclerosis and Demyelinating Disorders. https://doi.org/10.1186/s40893-016-0010-2

Vancouver

Comi G, Amato MP, Bertolotto A, Centonze D, Stefano ND, Farina C, et al. The heritage of glatiramer acetate and its use in multiple sclerosis. Multiple Sclerosis and Demyelinating Disorders. 2016. doi:10.1186/s40893-016-0010-2

BibTeX
@article{Comi2016,
  author = {Comi, Giancarlo and Amato, Maria Pia and Bertolotto, Antonio and Centonze, Diego and Stefano, Nicola De and Farina, Cinthia and Gallo, Paolo and Ghezzi, Angelo and Grimaldi, Luigi Maria and Mancardi, Gianluigi and Marrosu, Maria Giovanna and Montanari, Enrico and Patti, Francesco and Pozzilli, Carlo and Provinciali, Leandro and Salvetti, Marco and Tedeschi, Gioacchino and Trojano, Maria},
  title = {The heritage of glatiramer acetate and its use in multiple sclerosis},
  journal = {Multiple Sclerosis and Demyelinating Disorders},
  year = {2016},
  doi = {10.1186/s40893-016-0010-2}
}
Kostenlos starten →